市場調査レポート
商品コード
1059112

糖尿病性神経障害治療薬の世界市場 (2021年~2025年)

Global Diabetic Neuropathy Drugs Market 2021-2025

出版日: | 発行: TechNavio | ページ情報: 英文 120 Pages | 納期: 即納可能 即納可能とは

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=152.41円
糖尿病性神経障害治療薬の世界市場 (2021年~2025年)
出版日: 2022年01月18日
発行: TechNavio
ページ情報: 英文 120 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 目次
概要

世界の糖尿病性神経障害治療薬の市場規模は、2021年~2025年の間に23億7,000万米ドルの増加が見込まれ、予測期間中に12.20%のCAGRで成長すると予測されています。

市場を牽引しているは、糖尿病性神経障害の有病率の増加、及び、新薬の承認と強力な医薬品パイプラインです。今後も、糖尿病性神経障害の有病率の増加が、市場の成長を後押しすると予想されています。

当レポートでは、世界の糖尿病性神経障害治療薬市場について調査分析し、全体的な分析、市場規模と予測、動向、成長促進要因、課題のほか、約25社のベンダーを対象としたベンダー分析を提供しています。

目次

エグゼクティブサマリー

市場情勢

  • 市場のエコシステム
  • バリューチェーン分析

市場規模

  • 市場の定義
  • 市場セグメント分析
  • 市場規模 (2020年)
  • 市場の見通し:2020年~2025年の予測

ファイブフォース分析

  • ファイブフォースの要約
  • 買い手の交渉力
  • 供給企業の交渉力
  • 新規参入業者の脅威
  • 代替品の脅威
  • ライバルの脅威
  • 市況

製品別の市場セグメンテーション

  • 市場セグメント
  • 製品別の比較
  • カルシウムチャネルアルファ-2-デルタリガンド - 市場規模と予測 (2020年~2025年)
  • SNRIとTCA - 市場規模と予測 (2020年~2025年)
  • 製品別の市場機会

顧客情勢

  • 概要

地域別の情勢

  • 地域別のセグメンテーション
  • 地域別の比較
  • 北米 - 市場規模と予測 (2020年~2025年)
  • 欧州 - 市場規模と予測 (2020年~2025年)
  • 欧州 - 市場規模と予測 (2020年~2025年)
  • その他の地域 - 市場規模と予測 (2020年~2025年)
  • 主要国
  • 地域情勢別の市場機会

促進要因、課題、および動向

  • 市場促進要因
  • 市場の課題
  • 市場動向

ベンダー情勢

  • 概要
  • 混乱の状況
  • 競合情勢

ベンダー分析

  • 対象ベンダー
  • ベンダーの市場ポジショニング
  • Alnylam Pharmaceuticals Inc.
  • Astellas Pharma Inc.
  • AstraZeneca Plc
  • Daiichi Sankyo Co. Ltd.
  • Eli Lilly and Co.
  • Grunenthal GmbH
  • Johnson and Johnson Inc.
  • NeuroBo Pharmaceuticals Inc.
  • Novartis AG

付録

目次
Product Code: IRTNTR72073

Technavio has been monitoring the diabetic neuropathy drugs market and it is poised to grow by $ 2.37 bn during 2021-2025, progressing at a CAGR of 12.20% during the forecast period. Our report on the diabetic neuropathy drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the increasing prevalence of diabetic neuropathy and new drug approvals and strong drug pipeline. In addition, the increasing prevalence of diabetic neuropathy is anticipated to boost the growth of the market as well.

The diabetic neuropathy drugs market analysis includes the product segment and geographic landscape.

Technavio's diabetic neuropathy drugs market is segmented as below:

By Product

  • Calcium channel alpha-2-delta ligand
  • SNRIs and TCAs
  • Others

By Geographical Landscape

  • North America
  • Europe
  • Asia
  • ROW

This study identifies the rising awareness about diabetic neuropathyas one of the prime reasons driving the diabetic neuropathy drugs market growth during the next few years.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on diabetic neuropathy drugs market covers the following areas:

  • Diabetic neuropathy drugs market sizing
  • Diabetic neuropathy drugs market forecast
  • Diabetic neuropathy drugs market industry analysis

Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading diabetic neuropathy drugs market vendors that include Alnylam Pharmaceuticals Inc., Astellas Pharma Inc., AstraZeneca Plc, Daiichi Sankyo Co. Ltd., Eli Lilly and Co., Grunenthal GmbH, Johnson and Johnson Inc., NeuroBo Pharmaceuticals Inc., Novartis AG, and Pfizer Inc. Also, the diabetic neuropathy drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Table of Contents

  • Executive Summary
    • Market Overview
  • Market Landscape
    • Market ecosystem
    • Value chain analysis
  • Market Sizing
    • Market definition
    • Market segment analysis
    • Market size 2020
    • Market outlook: Forecast for 2020 - 2025
  • Five Forces Analysis
    • Five Forces Summary
    • Bargaining power of buyers
    • Bargaining power of suppliers
    • Threat of new entrants
    • Threat of substitutes
    • Threat of rivalry
    • Market condition
  • Market Segmentation by Product
    • Market segments
    • Comparison by Product
    • Calcium channel alpha-2-delta ligand - Market size and forecast 2020-2025
    • SNRIs and TCAs - Market size and forecast 2020-2025
    • Market opportunity by Product
  • Customer landscape
    • Overview
  • Geographic Landscape
    • Geographic segmentation
    • Geographic comparison
    • North America - Market size and forecast 2020-2025
    • Europe - Market size and forecast 2020-2025
    • Europe - Market size and forecast 2020-2025
    • ROW - Market size and forecast 2020-2025
    • Key leading countries
    • Market opportunity By Geographical Landscape
  • Drivers, Challenges, and Trends
    • Market drivers
    • Market challenges
    • Market trends
  • Vendor Landscape
    • Overview
    • Landscape disruption
    • Competitive landscape
  • Vendor Analysis
    • Vendors covered
    • Market positioning of vendors
    • Alnylam Pharmaceuticals Inc.
    • Astellas Pharma Inc.
    • AstraZeneca Plc
    • Daiichi Sankyo Co. Ltd.
    • Eli Lilly and Co.
    • Grunenthal GmbH
    • Johnson and Johnson Inc.
    • NeuroBo Pharmaceuticals Inc.
    • Novartis AG
  • Appendix
    • Scope of the report
    • Currency conversion rates for US$
    • Research Methodology
    • List of abbreviations
  • 1: Key Finding 1
  • 2: Key Finding 2
  • 3: Key Finding 3
  • 4: Key Finding 5
  • 5: Key Finding 6
  • 6: Key Finding 7
  • 7: Key Finding 8
  • 8: Parent market
  • 9: Market characteristics
  • 10: Offerings of vendors included in the market definition
  • 11: Market segments
  • 12: Global - Market size and forecast 2020 - 2025 ($ million)
  • 13: Global market: Year-over-year growth 2020 - 2025 (%)
  • 14: Five forces analysis 2020 & 2025
  • 15: Bargaining power of buyers
  • 16: Bargaining power of suppliers
  • 17: Threat of new entrants
  • 18: Threat of substitutes
  • 19: Threat of rivalry
  • 20: Market condition - Five forces 2020
  • 21: Product - Market share 2020-2025 (%)
  • 22: Comparison by Product
  • 23: Calcium channel alpha-2-delta ligand - Market size and forecast 2020-2025 ($ million)
  • 24: Calcium channel alpha-2-delta ligand - Year-over-year growth 2020-2025 (%)
  • 25: SNRIs and TCAs - Market size and forecast 2020-2025 ($ million)
  • 26: SNRIs and TCAs - Year-over-year growth 2020-2025 (%)
  • 27: Others - Market size and forecast 2020-2025 ($ million)
  • 28: Others - Year-over-year growth 2020-2025 (%)
  • 29: Market opportunity by Product
  • 30: Customer landscape
  • 31: Market share By Geographical Landscape 2020-2025 (%)
  • 32: Geographic comparison
  • 33: North America - Market size and forecast 2020-2025 ($ million)
  • 34: North America - Year-over-year growth 2020-2025 (%)
  • 35: Europe - Market size and forecast 2020-2025 ($ million)
  • 36: Europe - Year-over-year growth 2020-2025 (%)
  • 37: Asia - Market size and forecast 2020-2025 ($ million)
  • 38: Asia - Year-over-year growth 2020-2025 (%)
  • 39: ROW - Market size and forecast 2020-2025 ($ million)
  • 40: ROW - Year-over-year growth 2020-2025 (%)
  • 41: Key leading countries
  • 42: Market opportunity By Geographical Landscape ($ million)
  • 43: Impact of drivers and challenges
  • 44: Vendor landscape
  • 45: Landscape disruption
  • 46: Industry risks
  • 47: Vendors covered
  • 48: Market positioning of vendors
  • 49: Alnylam Pharmaceuticals Inc. - Overview
  • 50: Alnylam Pharmaceuticals Inc. - Product and service
  • 51: Alnylam Pharmaceuticals Inc. - Key offerings
  • 52: Alnylam Pharmaceuticals Inc. - Key customers
  • 53: Alnylam Pharmaceuticals Inc. - Segment focus
  • 54: Astellas Pharma Inc. - Overview
  • 55: Astellas Pharma Inc. - Product and service
  • 56: Astellas Pharma Inc. - Key offerings
  • 57: Astellas Pharma Inc. - Key customers
  • 58: Astellas Pharma Inc. - Segment focus
  • 59: AstraZeneca Plc - Overview
  • 60: AstraZeneca Plc - Product and service
  • 61: AstraZeneca Plc - Key offerings
  • 62: AstraZeneca Plc - Key customers
  • 63: AstraZeneca Plc - Segment focus
  • 64: Daiichi Sankyo Co. Ltd. - Overview
  • 65: Daiichi Sankyo Co. Ltd. - Business segments
  • 66: Daiichi Sankyo Co. Ltd. - Key offerings
  • 67: Daiichi Sankyo Co. Ltd. - Key customers
  • 68: Daiichi Sankyo Co. Ltd. - Segment focus
  • 69: Eli Lilly and Co. - Overview
  • 70: Eli Lilly and Co. - Business segments
  • 71: Eli Lilly and Co. - Key offerings
  • 72: Eli Lilly and Co. - Key customers
  • 73: Eli Lilly and Co. - Segment focus
  • 74: Grunenthal GmbH - Overview
  • 75: Grunenthal GmbH - Product and service
  • 76: Grunenthal GmbH - Key offerings
  • 77: Grunenthal GmbH - Key customers
  • 78: Grunenthal GmbH - Segment focus
  • 79: Johnson and Johnson Inc. - Overview
  • 80: Johnson and Johnson Inc. - Business segments
  • 81: Johnson and Johnson Inc. - Key offerings
  • 82: Johnson and Johnson Inc. - Key customers
  • 83: Johnson and Johnson Inc. - Segment focus
  • 84: NeuroBo Pharmaceuticals Inc. - Overview
  • 85: NeuroBo Pharmaceuticals Inc. - Product and service
  • 86: NeuroBo Pharmaceuticals Inc. - Key offerings
  • 87: NeuroBo Pharmaceuticals Inc. - Key customers
  • 88: NeuroBo Pharmaceuticals Inc. - Segment focus
  • 89: Novartis AG - Overview
  • 90: Novartis AG - Business segments
  • 91: Novartis AG - Key offerings
  • 92: Novartis AG - Key customers
  • 93: Novartis AG - Segment focus
  • 94: Pfizer Inc. - Overview
  • 95: Pfizer Inc. - Business segments
  • 96: Pfizer Inc. - Key offerings
  • 97: Pfizer Inc. - Key customers
  • 98: Pfizer Inc. - Segment focus
  • 99: Currency conversion rates for US$
  • 100: Research Methodology
  • 101: Validation techniques employed for market sizing
  • 102: Information sources
  • 103: List of abbreviations